ASXL1 IS A MOLECULAR PREDICTOR IN IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE

EHA Library, Dong-Yeop Shin, 214944

MUTATIONAL PROFILE IN LOW RISK MDS WITHOUT RING SIDEROBLASTS

EHA Library, Maria Abaigar, 214945

COMPARISON OF MUTATION DYNAMICS IN HIGHER RISK MYELODYSPLASTIC SYNDROME PATIENTS TREATED WITH AZACITIDINE AND DECITABINE

EHA Library, Joon Ho Moon, 214946

USING PU.1 AND JUN DIMERIZATION PROTEIN 2 TRANSCRIPTION FACTOR EXPRESSION IN MYELODYSPLASTIC SYNDROMES TO PREDICT TREATMENT RESPONSE AND LEUKEMIA TRANSFORMATION

EHA Library, Ciro Rinaldi, 214947

ASSOCIATION OF EMERGENT PTPN11 MUTATIONS WITH CLINICAL RESISTANCE TO THE COMBINATION OF AZACTIDINE AND RIGOSERTIB IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME

EHA Library, Lewis Silverman, 214948

A NOVEL CULTURE MODEL FOR STUDYING TERMINAL ERYTHROID DIFFERENTIATION IN PATIENTS WITH SF3B1 MUTATED MYELODYSPLASTIC SYNDROMES

EHA Library, Edda Elvarsdóttir, 214949

PROGNOSTIC SIGNIFICANCE OF THE ASXL1 GENE ALTERATION IN PATIENTS WITH ISOLATED 20Q DELETION

EHA Library, Jana Brezinova, 214950

PARP1 EXPRESSION PROFILE AND DIVERGENT CLINICAL IMPACT IN MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA.

EHA Library, Ana María Hurtado López, 214951

MECHANISTIC CHARACTERIZATION OF HDACI MEDIATED KIT DOWNREGULATION IN SYSTEMIC MASTOCYTOSIS

EHA Library, Katarina Lyberg, 214953

MYELODYSPLASTIC SYNDROMES WITH HYPOCELLULAR MARROW: CLINICAL CHARACTERISTICS AND EVALUATION OF OUTCOME

EHA Library, Valeria SANTINI, 214954

DESCRIPTION OF MUTATIONAL PROFILE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES AT THE TIME OF LEUKEMIC PROGRESSION

EHA Library, Begoña Pedrote, 214955

CLONAL EVOLUTION IS MUCH MORE FREQUENT IN MDS AS KNOWN AS YET

EHA Library, Christina Ganster, 214956

MUTATIONAL AND SUBGROUP ANALYSES OF LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS TREATED WITH LUSPATERCEPT: PHASE 2 PACE-MDS STUDY

EHA Library, Uwe Platzbecker, 214957

ROLE OF SOMATIC MUTATIONS IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH ERYTHROPOIESIS STIMULATING AGENTS

EHA Library, María Díez Campelo, 214958

MOLECULAR SCORING SYSTEM INTEGRATED WITH IPSS-R IN KOREAN MYELODYSPLASTIC SYNDROME

EHA Library, Hee Sue Park, 214959

FLOW CYTOMETRY ANALYSIS OF ERYTHROPOIETIC MATURATION PATTERNS HELP TO DIAGNOSE AND FOLLOW-UP ERYTHROPOIETIC DYSPLASIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Despoina Violidaki, 214960

MUTATIONS AND KARYOTYPE PREDICT TREATMENT RESPONSE IN MYELODYSPLASTIC SYNDROMES

EHA Library, Dame Idossa, 214961

GENDER AND THE PATTERN OF RECURRENT MYELOID MUTATIONS ARE STRONGLY AND INDEPENDENTLY ASSOCIATED TO BLOOD TRANSFUSION INTENSITY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Jenny Rydén, 214962

DIFFERENCES IN MUTATIONAL PROFILE AND CLONAL ARCHITECTURE OF MYELODYSPLASTIC SYNDROMES WITH ISOLATED DELETION OF 5Q, HYPERPLASTIC AND HYPOPLASTIC MYELODYSPLASTIC SYNDROMES

EHA Library, Francisca Hernandez Mohedo, 214963

CLINICAL SIGNIFICANCE OF REDUCED EXPRESSION OF THE GENES LOCATED WITHIN COMMON DELETED REGION OF DEL(20Q) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Masayuki SHISEKI, 214964

HIGH WT1 EXPRESSION LEVELS AT DIAGNOSIS PREDICTED POOR OUTCOMES OF PATIENTS PRESENTING ISOLATED THROMBOCYTOPENIA AT ONSET OF MYELODYSPLASTIC SYNDROME

EHA Library, Qiu-Sha Huang, 214965

ROLE OF DNA METHYLATION GENE AND TP53 MUTATIONS IN PREDICTING THE CLINICAL EFFICACY OF EPIGENETIC THERAPY IN MYELOID NEOPLASM PATIENTS - META ANALYSIS

EHA Library, Li Cai, 214966

MUTATIONS IN 19S PROTEASOME SUBUNITS REPRESENT A NOVEL MECHANISM OF ACQUIRED RESISTANCE TO PROTEASOME INHIBITORS IN MULTIPLE MYELOMA PATIENTS

EHA Library, Santiago Barrio, 214967

KRAS BUT NOT NRAS MUTATIONS ARE ASSOCIATED WITH A FAVORABLE OVERALL SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH INTENSIVE THERAPY

EHA Library, Jan Krönke, 214968

MOLECULAR MECHANISMS OF THE ACTIVITY OF THE NOVEL C-MYC TARGETED-COMPOUND IDP-501 IN MM

EHA Library, Enrique Ocio, 214969

SNPS ARRAY ANALYSIS OF COPY NUMBER ALTERATIONS (CNAS) IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS: DEFINITION OF A PROGNOSTIC RISK-CLASSIFIER.

EHA Library, Carolina Terragna, 214970

CD26 IS A POTENTIAL THERAPEUTIC TARGET BY HUMANIZED MONOCLONAL ANTIBODY IN MULTIPLE MYELOMA

EHA Library, Hiroko Nishida, 214971

DNA REPAIR PROCESSES TARGET TRANSCRIBED REGION IN MULTIPLE MYELOMA

EHA Library, Nikhil Munshi, 214972

EFFECT OF DARATUMUMAB ON NORMAL PLASMA CELLS, POLYCLONAL IMMUNOGLOBULINS AND VACCINATION RESPONSES IN EXTENSIVELY PRETREATED MYELOMA PATIENTS

EHA Library, Kristine Frerichs, 214973

STUDY OF PLASMA CELL TRASCRIPTOME IN SMOLDERING MYELOMA PATIENTS IN RELATIONSHIP TO PROGRESSION TO ACTIVE MULTIPLE MYELOMA.

EHA Library, Paola Storti, 214974

LONGITUDINAL CHROMOSOMAL ABNORMALITIES ANALYSIS IN MULTIPLE MYELOMA DISEASE PROGRESSION REVEALS CLONAL EVOLUTION AFTER THERAPY.

EHA Library, Stefania Oliva, 214975

MYTYPE TARGETED NEXT GENERATION SEQUENCING ASSAY FOR DETECTION OF IGH TRANSLOCATIONS AND COPY NUMBER ALTERATIONS IN MULTIPLE MYELOMA

EHA Library, Malin Hultcrantz, 214976

RAPID AND SCALABLE GENOME-WIDE PROFILING OF CLINICALLY RELEVANT GENETIC ABERRATIONS IN MULTIPLE MYELOMA

EHA Library, Donat Alpar, 214977

INDUCTION OF STRUCTURAL AND FUNCTIONAL EFFECTS ON MYELOMA CELLS AFTER DARATUMUMAB TREATMENT

EHA Library, Angelo Corso Faini, 214978

RNA-SEQ BASED RISK STRATIFICATION IN MULTIPLE MYELOMA PATIENTS VALIDATES SKY92 AS A HIGH RISK MARKER IN THE COMMPASS TRIAL

EHA Library, Rowan Kuiper, 214979

MDSCS CONTRIBUTE TO CANCER STEM CELLS ACCUMULATION VIA PIRNA 823 UPREGULATION AND DE NOVO DNA METHYLATION IN MULTIPLE MYELOMA

EHA Library, Lisha Ai, 214980

MESENCHYMAL STROMAL CELL SIALYATION ENHANCES IMMUNE SUPPRESSION: IMPLICATIONS IN MULTIPLE MYELOMA

EHA Library, Kevin Lynch, 214981

LOW-PASS SEQUENCING OF PLASMA CELL DNA AND OF CIRCULATING CELL-FREE DNA FOR THE DETECTION OF COPY NUMBER ABERRATIONS AND EARLY RESPONSE MONITORING IN MULTIPLE MYELOMA

EHA Library, Barbara Dewaele, 214982

RNA-SEQ ANALYSIS UNRAVELS SPECIFIC LONG NON-CODING RNA TRANSCRIPTIONAL FINGERPRINTS IN MULTIPLE MYELOMA SUBTYPES

EHA Library, Elisa Taiana, 214983

COMBINATION TARGETING OF SIALYLATION AND THE PROTEASOME INHIBITS TUMOR GROWTH AND INCREASES SURVIVAL IN A HUMANIZED MOUSE MULTIPLE MYELOMA MODEL

EHA Library, Michaela Reagan, 214984

ACTIVATION OF NFAT (NUCLEAR FACTOR OF ACTIVATED T CELLS) SIGNALING AND INDUCTION OF AUTOPHAGY CONFER BORTEZOMIB RESITSTANCE IN MULTIPLE MYELOMA

EHA Library, Margaret HL Ng, 214985

THE CONICAL AGAROSE MICROWELL ARRAY (CAMA) ENABLES 3D LONG-TERM CULTIVATION OF PRIMARY SAMPLES AND ENHANCED HIGH THROUGHPUT SCREENING FOR RATIONAL EPIGENTIC/ANTIBODY COMBINATION IN MULTIPLE MYELOMA

EHA Library, Stefan Müller, 214986

ENHANCED CYTOTOXICITY OF MULTIPLE MYELOMA CELLS USING DARATUMUMAB IN COMBINATION WITH NK CELLS ENGINEERED TO EXPRESS HIGH-AFFINITY CD16 (F158V)

EHA Library, Michael O'Dwyer, 214987

IMMUNOLOGICAL PROFILING BY MASS CYTOMETRY REVEALS THAT TIM3 EXPRESSION IS REDUCED ON NK CELL SUBSETS IN NEWLY DIAGNOSED MYELOMA AND IS ASSOCIATED WITH LOSS OF NK FUNCTION AND DECREASED SURVIVAL

EHA Library, Frances Seymour, 214988

AUTOLOGOUS STEM CELL TRANSPLANTATION AS A MODEL FOR ACCELERATED T-CELL AGING

EHA Library, Fabienne Lucas, 214989

GENE EXPRESSION PROFILING OF PROSPECTIVE SERIES IN PRIMARY PLASMA CELL LEUKEMIA REVEALED GENE SIGNATURE ASSOCIATED WITH SURVIVAL

EHA Library, Marie naudot, 214990

MDSCS PROMOTED TUMORIGENESIS OF MULTIPLE MYELOMA BOTH IN VITRO AND IN VIVO.

EHA Library, Lisha Ai, 214991

TARGETING THE INTERACTION OF MULTIPLE MYELOMA AND THE BONE MARROW MICROENVIRONMENT THROUGH NOVEL SMALL MOLECULES DIRECTED TO NOTCH PATHWAY

EHA Library, Maria Teresa Palano, 214992

EXPRESSION LEVELS OF THE THREE GENES CRBN, IKZF1, AND IKZF3 IN PRIMARY MULTIPLE MYELOMA CELLS AT PRE- AND POST- LENALIDOMIDE TREATMENT

EHA Library, Shiori kinoshita, 214993

MYC INVOLVES MULTIPLE MYELOMA PROGRESSION BY ATTENUATING TUMOR SUPPRESSIVE FUNCTION OF TP53-MICRO RNA 34 AXIS

EHA Library, Yuki Murakami, 214994

PREVENTING AND REPAIRING MYELOMA BONE DISEASE BY COMBINING CONVENTIONAL ANTI-RESORPTIVE TREATMENT WITH A NOVEL BONE ANABOLIC TREATMENT

EHA Library, Andrew Chantry, 214995

TRYPTOPHAN SHORTAGE DUE TO IDO-1 EXPRESSED BY HIGH-DENSITY NEUTROPHILS INDUCE IMMUNE-SUPPRESSION AND PLASMA CELL FITNESS IN MULTIPLE MYELOMA

EHA Library, ALESSANDRA ROMANO, 214996

CHARACTERIZATION OF ST3GAL6-AS1, A NOVEL LNCRNA DEREGULATED IN MULTIPLE MYELOMA

EHA Library, Cristina Vinci, 214997

MULTIPLE MYELOMA RELATED ANGIOGENESIS: ROLE OF NOTCH-JAG AXIS IN MODULATING ENDOTHELIAL CELLS BEHAVIOR

EHA Library, Maria Teresa Palano, 214998

ADIPORON, THE FIRST ORAL ADIPONECTIN RECEPTOR AGONIST, INHIBITS THE PROLIFERATION OF MYELOMA CELLS VIA THE AMPK / MTOR /AUTOPHAGY SIGNALING PATHWAY

EHA Library, Shujuan Wang, 214999

CLINICAL RELEVANCE OF LONG NON CODING RNA IN MULTIPLE MYELOMA: RETROSPECTIVE MONOCENTRIC STUDY

EHA Library, valeria ferla, 215000

DRUG SENSITIVITY SCREENING IN MULTIPLE MYELOMA (MM) FOR PRECISION CANCER THERAPY

EHA Library, Deepak balaji Thimiri Govinda Raj, 215001

ASSESSMENT OF SELECTED TOLL-LIKE RECEPTORS EXPRESSION ONT AND B LYMPHOCYTES IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE

EHA Library, Ewelina Grywalska, 215002

DISCOVERY BLOOD PLASMA PROTEOMICS IN ELUCIDATING BIOMARKERS TO DISTINGUISH ONSET OF LETHAL MULTIPLE MYELOMA IN PREMALIGNANT MGUS

EHA Library, Luz Yurany Moreno Rueda, 215003

VARIABLES PREDICTIVE OF POOR PROGNOSIS IN PATIENTS WITH MAYO STAGE 1 SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

EHA Library, Faye Sharpley, 215004

SINGLE AGENT CARFILZOMIB PROLONGS PFS FOLLOWING TRIPLET THERAPY WITH CYCLOPHOSPHAMIDE & DEXAMETHASONE FOR FIRST RELAPSE/PRIMARY REFRACTORY MULTIPLE MYELOMA: PHASE 2 MUKFIVE STUDY, SECOND ANALYSIS

EHA Library, Kwee Yong, 215005

SUBCUTANEOUS DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: PART 2 UPDATE OF THE OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE 1B STUDY (PAVO)

EHA Library, Jesús San Miguel, 215006

LEVOFLOXACIN PROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA REDUCES FEBRILE EPISODES AND DEATH WITHOUT INCREASING HEALTHCARE ASSOCIATED INFECTIONS: RESULTS FROM THE TEAMM TRIAL

EHA Library, Stella Bowcock, 215007

PHASE 2 STUDY OF VENETOCLAX PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Luciano J. Costa, 215008

A NOVEL RISK-STRATIFICATION ALGORITHM FOR RELAPSED MULTIPLE MYELOMA (RMM): ASSESSMENT OF PERFORMANCE AND VALIDATION USING REAL-WORLD PATIENT DATA FROM FRANCE, GERMANY AND THE UNITED KINGDOM

EHA Library, Roman Hájek, 215009

CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MULTICENTER PHASE IB/II TRIAL OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP (EMNTG)

EHA Library, Francesca Gay, 215010

CARFILZOMIB AND DEXAMETHASONE (KD56) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED OVERALL SURVIVAL (OS), SAFETY, AND SUBGROUP ANALYSIS OF ENDEAVOR

EHA Library, Robert Orlowski, 215011

MAINTENANCE AFTER LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE INDUCTION AND TRANSPLANT IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND HIGH-RISK CYTOGENETICS: AN ENHANCED MEDICAL RECORD ANALYSIS

EHA Library, Rafael Fonseca, 215012

EUROPEAN POST-APPROVAL SAFETY STUDY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SAFETY IN PATIENTS TREATED WITH POMALIDOMIDE IN A REAL-WORLD SETTING

EHA Library, Martin Schmidt-Hieber, 215013

IMPACT OF PRIOR MALIGNANCIES ON THE DEVELOPMENT OF SUBSEQUENT MALIGNANCIES AND SURVIVAL IN MULTIPLE MYELOMA: A NATIONWIDE POPULATION-BASED STUDY IN THE NETHERLANDS

EHA Library, Mirian Brink, 215014

A PHASE IB STUDY OF ATEZOLIZUMAB (ATEZO) ALONE OR IN COMBINATION WITH LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM)

EHA Library, Hearn Cho, 215015

TIME TO PLATEAU AS A PREDICTOR OF SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Patrick Mellors, 215016

SAFETY AND EFFICACY OF POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IMMEDIATELY FOLLOWING LENALIDOMIDE-BASED TREATMENT FAILURE IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

EHA Library, David S. Siegel, 215017

PRE-TREATMENT CD38 EXPRESSION LEVELS IN MYELOMA CELLS AND CD38-POSITIVE REGULATORY T CELLS AFFECT THE RESPONSE OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TO TREATMENT WITH DARATUMUMAB

EHA Library, Akihiro Kitadate, 215018

UPDATED RESULTS OF A PHASE II STUDY WITH CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCD) FOR NEWLY DIAGNOSED TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS.

EHA Library, Alessandra Larocca, 215019

DEVELOPMENT OF A PREDICTIVE MODEL OF MULTIPLE MYELOMA (MM) PATIENT OUTCOMES BASED ON TREATMENT (TX) SEQUENCING USING DATA FROM THE CONNECT® MM PATIENT REGISTRY

EHA Library, Sundar Jagannath, 215020

EXTERNAL VALIDATION OF THE MULTIPLE MYELOMA (MM) RISK-STRATIFICATION ALGORITHM IN A REAL-WORLD GREEK DATA SET

EHA Library, Evangelos Terpos, 215021

RANDOMIZED PHASE II STUDY TO OPTIMIZE MELPHALAN, PREDNISOLONE AND BORTEZOMIB (MPB) IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG1105)

EHA Library, Dai Maruyama, 215022

REAL-WORLD TREATMENT PATTERNS AND PROGRESSION-FREE SURVIVAL (PFS) AMONG PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING POMALIDOMIDE-BASED REGIMENS

EHA Library, Ravi Vij, 215023

TIME TO FIRST ONSET OF TREATMENT-EMERGENT ADVERSE EVENTS (TEAES) OF INTEREST: A POST-HOC ANALYSIS FROM ASPIRE AND ENDEAVOR TRIALS

EHA Library, Maria Victoria Mateos, 215024

SMOLDERING MYELOMA AFTER IMWG UPDATE: FACTORS PREDICTIVE OF EVOLUTION, ROLE OF ADVANCED IMAGING AND OF CLINICAL JUDGEMENT. A REAL-LIFE RETROSPECTIVE EXPERIENCE

EHA Library, AM Morelli, 215025

SAFETY OUTCOMES IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH LENALIDOMIDE FOR ≤ 24 MONTHS VS > 24 MONTHS IN A EUROPEAN POST-APPROVAL SAFETY STUDY (EU PASS)

EHA Library, Gianpietro Semenzato, 215026

CLINICAL CHARACTERISTICS AND OUTCOMES OF OLIGOSECRETORY AND NON-SECRETORY MULTIPLE MYELOMA

EHA Library, Efstathios Kastritis, 215027

SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN INDEPENDENTLY PREDICTS FOR RENAL RESPONSE IN MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT

EHA Library, Efstathios Kastritis, 215028

DARATUMUMAB, CARFILZOMIB, AND DEXAMETHASONE (D-KD) IN LENALIDOMIDE-REFRACTORY PATIENTS WITH RELAPSED MULTIPLE MYELOMA (MM): SUBGROUP ANALYSIS OF MMY1001

EHA Library, Philippe Moreau, 215029

LONG-TERM RESULTS FROM THE HOVON-50 STUDY: IMPROVED SURVIVAL WITH THALIDOMIDE BEFORE AND AFTER TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Niels W.C.J. van de Donk, 215030

THE HORIZON STUDY: A PRELIMINARY REPORT ON EFFICACY AND SAFETY OF MELFLUFEN IN LATE STAGE RELAPSED-REFRACTORY MYELOMA (RRMM) PATIENTS REFRACTORY TO POMALIDOMIDE AND/OR DARATUMUMAB

EHA Library, Maria Victoria Mateos, 215031

PHASE I-B STUDY OF ISATUXIMAB + CARFILZOMIB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Thomas Martin, 215032

IMPACT OF BASELINE RENAL FUNCTION ON EFFICACY AND SAFETY OF DARATUMUMAB PLUS BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANTATION (ALCYONE)

EHA Library, Michele Cavo, 215033

UPDATE OF THE PHASE 2 STUDY OF CARFILZOMIB, THALIDOMIDE, AND LOW-DOSE DEXAMETHASONE AS INDUCTION/CONSOLIDATION IN NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA, CARTHADEX TRIAL

EHA Library, Ruth Wester, 215034

CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED PATIENTS WITH AL AMYLOIDOSIS WITH “NON-MEASURABLE” FREE LIGHT CHAINS: PROGNOSTIC IMPLICATIONS AND RESPONSE EVALUATION

EHA Library, Efstathios Kastritis, 215035

SELINEXOR COMBINED WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE (SPD) IN A RELAPSED / REFRACTORY MULTIPLE MYELOMA PATIENT POPULATION

EHA Library, Christine Chen, 215036

ABSENCE OF BONE DISEASE IS AN INDEPENDENT FAVORABLE PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN SYMPTOMATIC MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS

EHA Library, Eirini Katodritou, 215037

CORRELATION OF 11C-METHIONINE-PET AND FDG-PET IN MULTIPLE MYELOMA WITH MRD ASSESSMENT BY FLOWCYTOMETRY.

EHA Library, MARIA MARCOS JUBILAR, 215038

TRANSLOCATION (14;16) POSITIVE MULTIPLE MYELOMA PATIENTS: CLINICAL FEATURES AND SURVIVAL OUTCOMES OF A HIGH-RISK POPULATION.

EHA Library, Roberto Mina, 215039

THE SWEDISH MYELOMA REGISTRY: INCREASED SURVIVAL OVER TIME IN PATIENTS 66-80 YEARS OLD, DIAGNOSED 2008-2016

EHA Library, Cecilie Blimark, 215040

18F-FDG PET/CT AT DIAGNOSIS IS USEFUL FOR DETERMINING THE SURVIVAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA CLASSIFIED AS STAGE II WITH THE REVISED INTERNATIONAL STAGING SYSTEM

EHA Library, Sung-Hoon Jung, 215041

HAEMATOLOGICAL DIAGNOSIS AND MANAGEMENT IN MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE: SINGLE CENTRE EXPERIENCE

EHA Library, Ethan Troy-Barnes, 215042

IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA – DATA FROM THE CZECH REGISTRY OF MONOCLONAL GAMMOPATHIES

EHA Library, Jiri Minarik, 215043

ALLOGRAFT IN MULTIPLE MYELOMA: EXPERIENCE OF MULTIPLE MYELOMA GIMEMA LAZIO GROUP

EHA Library, Federico Vozella, 215044